Related Experiment Video
Updated: Jun 28, 2026
11:38
High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
Published on: May 10, 2016
[Hazard, risk and harm in clinical trials]
Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|October 24, 2008
Summary
Clinical trials pose various risks, including physical, psychological, and social harms, to participants and stakeholders. Increased awareness and education are crucial for mitigating these potential hazards in research.
Area of Science:
- Clinical Research Ethics
- Patient Safety
- Risk Management in Healthcare
Background:
- Clinical trials involve diverse stakeholders, including investigators, sponsors, and participants, who face potential physical, psychological, social, economic, legal, dignitary, and relational harms.
- Awareness of the full spectrum of risks associated with clinical trials remains insufficient among key personnel and the public.
- While substantial harms are infrequently reported, this may stem from a limited number of high-risk trials and a general lack of public understanding regarding potential adverse events.
Discussion:
- The multifaceted nature of clinical trial risks necessitates a comprehensive understanding beyond immediate physical consequences.
- Identifying and communicating all potential hazards is essential for informed consent and ethical conduct.
- The rarity of reported substantial harms might indicate underreporting or a concentration of risk in specific trial types.
Key Insights:
- Multiple stakeholder categories, beyond just participants, are exposed to various clinical trial hazards.
- A significant gap exists in the awareness of potential harms and risks inherent in clinical trial activities.
- Education is identified as a primary strategy to improve knowledge and management of clinical trial-related risks.
Outlook:
- Future efforts should focus on enhancing education and awareness programs for all clinical trial stakeholders.
- Developing standardized risk assessment and reporting protocols can improve the identification of potential harms.
- Promoting a culture of safety and transparency is vital for advancing ethical clinical research practices.
Related Concept Videos
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Hazard Rate
The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...